The IP Conversation You're Not Having With Your Cofounder

Most founding teams approach intellectual property the same way. They negotiate equity splits, divide responsibilities, and file the company documents. Then they move on. The question of who actually owns the intellectual property that makes the company worth something receives thirty seconds of attention, if it receives any at all.

That is a problem that compounds quietly and reveals itself at the worst possible moments: a cofounder departure, a diligence process, or a dispute with a prior employer. By the time any of those arrive, the cost of not having this conversation earlier has already accumulated.

WHAT THE COMPANY PROBABLY DOES NOT OWN

When two or more people start a company together, the assumption is that whatever they build belongs to the company. That assumption is frequently wrong.

Intellectual property does not follow effort or intention. It follows formal assignment. Work created before the company was formed does not automatically transfer to the entity when the entity comes into existence. Work created by a founder who has not signed an invention assignment agreement may belong to that founder personally, not to the company. Work created using resources from or during employment at a prior employer may trigger claims that have nothing to do with the new company's intentions.

For health tech founders, this is not a theoretical concern. The clinical protocol one cofounder developed at a prior employer. The diagnostic algorithm the technical cofounder built before the company existed. The data pipeline designed during the evenings of a prior job. These are often the assets that define the company's value. In many cases, the company does not actually own them.

Intellectual property does not follow effort or intention. It follows formal assignment. Founding a company together does not transfer ownership. Only documentation does.

THE COFOUNDER DEPARTURE PROBLEM

Cofounder separations are more common than most founding teams want to acknowledge. Research on early stage companies consistently shows that a significant portion of founding teams experience a cofounder departure within the first few years. When that departure happens in the absence of properly assigned IP, the departing cofounder may hold more leverage than anyone intended.

If a cofounder built core technology and never signed an invention assignment agreement, that cofounder leaves with something of value. Not equity subject to a vesting schedule. The actual intellectual property. The company cannot license, sell, or build on it without the former cofounder's consent. That creates leverage that shapes every subsequent negotiation: compensation, separation terms, future dealings.

The time to address this is not after the separation. It is before the company has any value worth arguing over. Once the asset is worth something, so is the leverage that comes from not having documentation in place.

A cofounder who leaves with unassigned IP has leverage you never intended to give them. Equity vests. Intellectual property without an assignment agreement does not disappear.

PRIOR EMPLOYER EXPOSURE

Founders who leave employment to start companies carry risk that travels with them. Most employment agreements include provisions assigning inventions developed during employment to the employer. Some of these provisions are narrow and well defined. Some are broad enough to capture work done entirely on personal time using personal equipment, depending on how the employer's business is described.

For founders coming out of healthcare organizations, medical device companies, research institutions, or life sciences firms, this exposure deserves careful attention. The clinical insight that became the product thesis, the workflow inefficiency observed on the job that the new product addresses, and the regulatory approach absorbed during years of prior employment all warrant a review. The line between general knowledge and assignable invention is not always obvious. Prior employers are not inclined to draw it generously when something valuable is at stake.

A clean IP schedule, a document identifying what each founder brings into the company that predates or sits outside the company's ownership, protects both the founder and the company. It requires honesty, creates a record, and limits the surface area for future disputes.

WHAT INVESTORS WILL FIND

Investors conducting diligence in a Series A or Series B transaction will review IP ownership. They will ask for invention assignment agreements from every founder and key employee. They will look for prior employer conflicts. They will ask whether any IP in use was developed before the company's formation.

What they are really asking is whether the company owns what it believes it owns.

A missing invention assignment from a cofounder, an identified prior employer with potential claims, or an IP schedule that surfaces assets the company never formally acquired: these findings create deal risk. They do not always terminate transactions. They delay them, provide leverage to investors in pricing negotiations, and require expensive remediation at precisely the moment when the founding team has the least available attention.

Companies that have addressed IP ownership thoroughly before a financing process close faster and on better terms than those that have not. The work is not glamorous. It does not feel urgent when there is a product to build. It matters when the conversation turns to who owns the product.

THE CONVERSATION WORTH HAVING

The IP conversation with a cofounder does not require an attorney to start. It requires honesty about four questions.

What did you build before we formed this company? Who did you work for before, and what did you agree to with that employer regarding inventions? What are you bringing into this company that came from somewhere else? And what will we document to confirm the company owns what it needs to own?

The legal instruments that follow, including invention assignment agreements, IP schedules, and representations in the operating agreement or shareholder agreement, are the formalization of those answers. They are not a substitute for the conversation. Founders who have the conversation and then document it are in a fundamentally different position than those who document without having it. The documentation protects against third parties. The conversation protects the relationship.

For health tech companies, add a fifth question: Is any part of what we are building subject to a potential claim by a prior employer, a clinical partner, a research institution, a government agency, or a grant condition?

The IP conversation is uncomfortable because it asks cofounders to look at each other with a degree of legal honesty they would rather avoid. Most cofounders have no intention of creating IP problems for the company. Intention does not create ownership. Documentation does. And the time to document is before the stakes are high enough to make it difficult.

If you have questions about IP assignment, cofounder agreements, or preparing your company for an investor diligence process, contact me.